A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of sub-Saharan West African Ancestry

Study identifier:D6800C00002

ClinicalTrials.gov identifier:NCT05351047

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 following Multiple Ascending Dose Administration to Healthy Male Participants of sub-Saharan West African Ancestry

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2373 subcutaneous injection, Placebo

Sex

Male

Actual Enrollment

24

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 04 Apr 2022
Primary Completion Date: 06 Jul 2023
Study Completion Date: 06 Jul 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Parexel International

Inclusion and exclusion criteria